Biosimilar Antibodies

Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody targeting the platelet-derived growth factor receptor alpha (PDGFRα). This antibody exhibits potent antitumor activity by inhibiting the PDGFRα pathway, which is implicated in various forms of cancer cell proliferation and tumor growth. Olaratumab is utilized primarily in research focused on the development and therapeutic intervention of malignancies where PDGFRα plays a critical role.

Precemtabart is a human monoclonal antibody of the IgG1κ subtype that specifically targets CEACAM5. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD1a Antibody (OKT-6) is a chimeric mouse monoclonal antibody of the IgG1 subtype, specifically designed to target human CD1a. For optimal experimental control, it is recommended to use Mouse IgG1 kappa as the isotype control. This product is ideal for research applications requiring precise targeting of the CD1a molecule.

Elipovimab is a potent, broadly neutralizing antibody designed for the targeted elimination of cells infected with HIV-1. This antibody binds specifically to the HIV-1 envelope protein, facilitating the recognition and destruction of infected cells by the immune system. Elipovimab's broad neutralizing capability makes it a valuable tool for research into the mechanisms of HIV infection and potential therapeutic interventions.

Nisevokitug (NIS-793) is a recombinant human IgG2λ monoclonal antibody specifically designed to target and neutralize transforming growth factor-beta (TGF-β), encompassing both TGFB1 and TGFB2 isoforms. This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Nisevokitug is utilized primarily in research focused on the modulation of TGF-β activity, which is crucial in various physiological and pathological processes including cell growth, inflammation, and fibrosis.

Fletikumab (NNC0109-0012) is a monoclonal antibody specifically designed to target interleukin-20 (IL-20). This antibody is utilized primarily in the study of inflammatory processes, with a focus on conditions such as rheumatoid arthritis. Fletikumab serves as a valuable tool in elucidating the role of IL-20 in inflammatory pathways and may contribute to the development of therapeutic strategies for managing rheumatoid arthritis and related inflammatory disorders.

Tusamitamab is an IgG1 monoclonal antibody specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes and tumor progression. This antibody serves as a foundational component in the synthesis of the antibody-drug conjugate (ADC) Tusamitamab ravtansine (SAR408701), highlighting its utility in targeted cancer therapy research.

Tucotuzumab is a recombinant IgG1 monoclonal antibody that specifically targets the human epithelial cell adhesion molecule (EpCAM). This antibody is engineered to conjugate two molecules of interleukin-2 (IL-2), enhancing its therapeutic potential. Tucotuzumab acts both as an immunosuppressant and an anti-tumor agent, making it a valuable tool for research in cancer immunotherapy and the study of epithelial cell biology.

Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody designed to selectively target and inhibit the exonuclease activity of CD73, an extracellular enzyme. By modulating the activity of CD73, Oleclumab influences the composition of bone marrow and lymphoid infiltrating leukocyte populations within the tumor microenvironment, demonstrating significant anti-tumor activity. This antibody is pivotal in studies focused on tumor immunology and the development of cancer immunotherapies.

Luveltamab is a human IgG1 κ monoclonal antibody targeting the folate receptor alpha (FOLR1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Geptanolimab (CBT-501) is a humanized IgG4 kappa monoclonal antibody that targets the programmed death-1 (PD-1) receptor. This antibody functions by competitively inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby modulating immune responses. Geptanolimab is primarily utilized in cancer research to investigate the therapeutic potential of PD-1 blockade in oncology.

Remtolumab (ABT-122) is a dual-variable domain immunoglobulin specifically engineered to neutralize tumor necrosis factor α (TNFα) and interleukin-17A (IL-17A). This biologic exhibits potent dual inhibition, effectively targeting both cytokines implicated in inflammatory processes. It is particularly useful in research focused on rheumatoid arthritis (RA), providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.

Sigvotatug is a human IgG1 κ monoclonal antibody targeting the integrin subunit beta 6 (ITGB6). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Vandortuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target STEAP1. This antibody comprises a human IgG1 type heavy chain and a human kappa type light chain, resulting in a predicted molecular weight of 148.74 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, a cell surface antigen predominantly expressed on T cells. This antibody functions by depleting T cells, reducing their activation, and inhibiting their proliferation. Additionally, Siplizumab promotes the enrichment of naïve and bona fide regulatory T cells. It is utilized primarily in research focused on immunological tolerance, autoimmunity, and transplantation immunology.

Pimivalimab (JTX-4014) functions as an inhibitor of the programmed cell death protein 1 (PD-1), a critical immune checkpoint receptor involved in downregulating immune responses and promoting self-tolerance by suppressing T cell inflammatory activity. This monoclonal antibody is specifically designed for the investigation of solid tumors in a research setting, providing a valuable tool for the study of immune checkpoint pathways and their role in cancer immunotherapy.

Onartuzumab (MetMAb) is a humanized, affinity-matured monovalent monoclonal antibody specifically targeting the MET receptor. This antibody effectively inhibits hepatocyte growth factor (HGF) binding, thereby preventing receptor phosphorylation and downstream signaling. Characterized by pharmacokinetics akin to those of typical antibodies, Onartuzumab demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development.

Penpulimab is a monoclonal antibody featuring an IgG1 backbone and is designed to target the PD-1 receptor, exhibiting potent antitumor activities. This antibody interferes with the PD-1 pathway, a critical immune checkpoint that inhibits T-cell activity, thus enhancing the immune system's ability to attack tumor cells. Penpulimab is primarily utilized in oncological research to investigate immune response modulation in various cancer models.

Eculizumab is a long-acting, humanized monoclonal antibody that specifically targets complement component C5. By inhibiting the cleavage of C5 into C5a and C5b, Eculizumab effectively prevents the activation of the terminal complement system, including the formation of the membrane attack complex (MAC). This antibody is particularly useful in research focused on hemolysis and other conditions related to complement system dysregulation.

The Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the F3 protein, also known as Factor III, Tissue Factor, or CD142, which plays a critical role in the initiation of blood coagulation. The antibody is comprised of a human IgG4 subclass heavy chain with an SP variant and a human kappa light chain. It exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa. This product is essential for research in hematology, particularly in studies involving coagulation pathways and cardiovascular disease mechanisms.

BI-1808 is a human IgG1 monoclonal antibody designed to selectively target TNFR2 (Tumor Necrosis Factor Receptor 2). It functions by inhibiting the interaction between TNFR2 and its ligand TNF-α. This antibody facilitates the FcγR-dependent depletion of regulatory T cells (Tregs) and promotes the expansion of CD8+ T cells within the tumor microenvironment. BI-1808 is utilized in research focused on modulating immune responses and studying the mechanisms of immune evasion in cancer.

Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This antibody is specifically designed for use in melanoma research, where it can help investigate the role of CTLA-4 in tumor immunity and potential therapeutic interventions.

The Anti-CD326/EpCAM Antibody (Ber-EP4) is a chimeric mouse monoclonal antibody of the IgG1 κ isotype, specifically designed to target human CD326, also known as Epithelial Cell Adhesion Molecule (EpCAM). This antibody has been engineered for high specificity and affinity toward the EpCAM antigen, a cell surface protein predominantly expressed in epithelial tissues and associated with cell signaling, migration, proliferation, and differentiation. It is commonly utilized in research focusing on cancer biology, particularly in studies involving carcinomas where EpCAM is often overexpressed. For accurate isotype control in experimental assays, the use of Mouse IgG1 kappa Isotype Control is recommended to ensure specificity and consistency in results.

Cergutuzumab is a fully human monoclonal antibody of the IgG1 isotype, specifically designed to target CEACAM5, a cell surface glycoprotein implicated in various cellular processes including cell adhesion and signaling. The recommended isotype control for experiments involving Cergutuzumab is Human IgG1 kappa, serving as a critical component for assessing the specificity and background activity of the antibody in various assays.

Ebronucimab (AK102) is a recombinant IgG1-λ2 monoclonal antibody specifically designed to target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This antibody is produced in Chinese Hamster Ovary (CHO) DG44 cells, ensuring high fidelity and consistency in antibody structure and function. Ebronucimab binds to PCSK9, inhibiting its ability to interact with the low-density lipoprotein receptor (LDLR), thereby modulating cholesterol metabolism. This makes it a valuable tool for research in cardiovascular diseases, lipid metabolism, and therapeutic development.

Tenatumomab (ST2146) is a murine monoclonal antibody developed to target tenascin-C, a large extracellular glycoprotein frequently overexpressed in various cancers. This antibody has demonstrated utility in advanced diagnostic and therapeutic techniques, including Pretargeted Antibody Guided Radioimmunotherapy (PAGRIT). Through PAGRIT, as well as direct labeling with 131-Iodine, tenatumomab facilitates the precise delivery of radionuclides to tumor sites, enhancing the specificity and efficacy of cancer imaging and treatment modalities.

Zamerovimab (CTB011) is a humanized IgG1κ monoclonal antibody designed to specifically bind to non-overlapping epitopes on the rabies virus (RABV) glycoprotein, focusing on residues at and near antigenic site III. This targeted binding capability makes Zamerovimab an essential tool for research in rabies, facilitating detailed studies on viral mechanisms and potential therapeutic interventions.

Enlonstobart is a human monoclonal antibody of the immunoglobulin G4-kappa subtype, specifically targeting the programmed cell death protein 1 (PD-1). This antibody acts as an immunostimulant and possesses antineoplastic properties, making it suitable for research in cancer immunotherapy and immune response modulation.

Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody specifically designed to target the p19 subunit of interleukin 23 (IL-23). This antibody demonstrates high affinity binding to IL-23 in both human and monkey models, with dissociation constants (Kd) of 21 pM and 55 pM, respectively. By selectively inhibiting the interaction between IL-23 and its receptor IL-23R, Mirikizumab effectively modulates the immune response. This mechanism of action suggests its utility in exploring therapeutic avenues for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease in research settings.

Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting the interaction between FcRn and the Fc portion of IgG molecules, Orilanolimab effectively impedes the activation of immune complexes (IC) mediated by FcRn. This action disrupts key pathways involved in IgG homeostasis, as well as innate and adaptive immune responses. This antibody is pivotal for research focused on the modulation of immune functions and the therapeutic regulation of antibody-mediated diseases.

BMS-986178 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target TNFRSF4, also known as OX40 or CD134. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Mitumomab is a mouse-derived IgG2b monoclonal antibody with anti-idiotypic properties, designed to mimic the structure of the ganglioside GD3. This antibody is primarily utilized in the study of small-cell lung carcinoma, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic targets of this aggressive cancer type.

Ocaratuzumab (AME 133v) is an Fc-engineered, humanized IgG1 monoclonal antibody targeting CD20, characterized by a dissociation constant (Kd) of approximately 100 pM. This antibody demonstrates enhanced efficacy in antibody-dependent cell-mediated cytotoxicity (ADCC), making it a potent candidate for research in immune-mediated therapeutic strategies.

Ublituximab, also known as LFB-R603, TG-1101, and TGTX-1101, represents a next-generation, type 1 chimeric monoclonal antibody designed to selectively bind to a unique epitope on the CD20 antigen. This targeting facilitates the induction of cytotoxic effects against CD20-expressing B cells, commonly implicated in various hematological malignancies. Ublituximab's mechanism of action and specificity make it a valuable tool in the research and treatment of cancer.

The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized monoclonal antibody specifically targeting CTSS/Cathepsin S, expressed in Chinese Hamster Ovary (CHO) cells. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control. This antibody is essential for research focusing on the role of CTSS/Cathepsin S in various biological processes and diseases.

GBR-900 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the TrkA/NTRK1 receptor. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

The Anti-SARS-80R monoclonal antibody (mAb) is a human IgG1 isotype produced in Chinese Hamster Ovary (CHO) cells. This antibody exhibits specific binding to the Spike (S1) protein of the SARS coronavirus, effectively blocking the virus's ability to infect susceptible cells. This mAb serves as a critical tool for research focused on the mechanisms of SARS virus entry and pathogenesis, and is suitable for use in virus neutralization studies and other virological applications.

Depatuxizumab is a brain-penetrant, humanized monoclonal antibody specifically targeting the epidermal growth factor receptor (EGFR). This antibody demonstrates selective inhibition of both mutant EGFRvIII and wild-type EGFR, effectively impeding the growth of xenograft models that express these receptors. Depatuxizumab is primarily utilized in cancer research, offering significant utility in the study of tumor biology and therapeutic antibody development.

Emugrobart is a humanized IgG1κ antibody that specifically targets GDF8 (Growth Differentiation Factor 8). For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control. This antibody is designed for precise specificity and is ideal for research focusing on muscle growth and differentiation pathways.

Riliprubart (SAR445088) is a humanized monoclonal antibody targeting C1s, a critical enzyme in the proximal segment of the classical complement pathway. This antibody selectively binds to activated C1s, effectively preventing its enzymatic activity on substrates C4 and C2. By inhibiting these interactions, Riliprubart impedes the formation of the classical pathway C3 convertase, C4b2a, thus modulating the immune response. This specific inhibition mechanism makes Riliprubart a valuable tool for research into immune regulation and the pathophysiology of diseases mediated by the classical complement system.

Siltuximab is a monoclonal antibody that targets interleukin-6 (IL-6), demonstrating significant antitumor activity. This antibody is utilized in the study of Multicentric Castleman's Disease (MCD) and is also applicable in research related to COVID-19, providing a valuable tool for investigating the role of IL-6 in these disease processes.

Ebrasodebart is a human monoclonal antibody of the IgG4λ subtype that specifically targets TMEM219. For experimental rigor, the recommended isotype control is Human IgG4 (S228P) lambda1. This control is crucial for distinguishing specific from non-specific binding in assays involving Ebrasodebart.

RG-7212 (RO5458640) is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting TNFSF12/TWEAK. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. The predicted molecular weight of RG-7212 is approximately 146.02 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Imalumab (BAX69) is a recombinant human IgG1 monoclonal antibody specifically designed to target macrophage migration inhibitory factor (MIF). This antibody is utilized primarily in the study of ovarian carcinoma, recurrent malignant ascites, and various cancers, providing a critical tool for researchers investigating the role of MIF in tumor biology and immune response modulation.

Dalnicastobart (LVGN-7409) is a human IgG1κ monoclonal antibody specifically designed to target CD40, also known as TNFRSF5. This antibody is engineered to bind selectively to CD40, a member of the tumor necrosis factor receptor superfamily, playing a crucial role in immune system regulation and the promotion of immune responses. Dalnicastobart is utilized predominantly in research focused on immunological responses and potential therapeutic interventions for autoimmune diseases and cancers.

Batoclimab is a fully humanized IgG1 monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn). This antibody is designed for use in research focused on autoimmune disorders, including myasthenia gravis and thyroid eye disease. Batoclimab's mechanism of action involves modulating the pathway of IgG recycling, potentially altering the autoimmune response. This makes it a valuable tool for studies aimed at understanding and treating conditions mediated by pathogenic autoantibodies.

LY2787106 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Hepcidin, also known as HAMP. This antibody is comprised of a human IgG4SP subtype heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 144.2 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa.

The Anti-HGFA Antibody is a humanized monoclonal antibody specifically targeting hepatocyte growth factor activator (HGFA). Expressed in Chinese hamster ovary (CHO) cells, this antibody is composed of a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 150 kDa. For isotype control, researchers should use the Human IgG1 kappa, Isotype Control, ensuring accurate experimental comparisons. This antibody is essential for studies involving the regulation and modulation of HGFA, a key enzyme in tissue repair and regeneration processes.

Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRPα with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRPα, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.

KY-1044 (Alomfilimab; SAR 445256) is a fully humanized IgG1 monoclonal antibody that selectively targets the inducible costimulatory receptor (ICOS). This antibody is designed to deplete ICOS-high expressing cells through the mechanism of antibody-dependent cellular cytotoxicity (ADCC), facilitated by the engagement of FcγRIIIa receptors. Additionally, KY-1044 serves as a costimulatory molecule for cells expressing lower levels of ICOS, such as CD8+ effector T cells, via FcγR-dependent clustering. This dual functionality allows KY-1044 to modulate the differential expression of ICOS across various T-cell subtypes, thereby enhancing the intratumoral immune contexture and promoting an effective antitumor immune response. KY-1044 is primarily researched for its potential therapeutic applications in oncology, focusing on its ability to manipulate immune responses within the tumor microenvironment.